Kari Keese - Axonics Modulation Chief Officer
AXNX Stock | USD 70.27 0.02 0.03% |
Executive
Kari Keese is Chief Officer of Axonics Modulation Technologies
Age | 39 |
Address | 26 Technology Drive, Irvine, CA, United States, 92618 |
Phone | 949 396 6322 |
Web | https://www.axonics.com |
Kari Keese Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kari Keese against Axonics Modulation stock is an integral part of due diligence when investing in Axonics Modulation. Kari Keese insider activity provides valuable insight into whether Axonics Modulation is net buyers or sellers over its current business cycle. Note, Axonics Modulation insiders must abide by specific rules, including filing SEC forms every time they buy or sell Axonics Modulation'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kari Keese a day ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese 2 days ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese 3 days ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 | ||
Kari Keese few days ago Disposition of 2083 shares by Kari Keese of Axonics Modulation subject to Rule 16b-3 |
Axonics Modulation Management Efficiency
Return On Tangible Assets is likely to drop to -0.01 in 2024. Return On Capital Employed is likely to drop to -0.0073 in 2024. At this time, Axonics Modulation's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 239.9 M in 2024, whereas Total Assets are likely to drop slightly above 371.4 M in 2024. Axonics Modulation's management efficiency ratios could be used to measure how well Axonics Modulation manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Julie Dewey | Orthofix Medical | 63 | |
Laurene Isip | Integra LifeSciences Holdings | N/A | |
Orit Wimpfheimer | Nano X Imaging | 53 | |
Deanna Wilke | LivaNova PLC | N/A | |
Dan Yarbrough | Orthofix Medical | N/A | |
Dylan John | Neuropace | N/A | |
Chad Patterson | iRhythm Technologies | 42 | |
Irina Ridley | Neuropace | 38 | |
John Webb | LivaNova PLC | N/A | |
John Ferrell | CONMED | 56 | |
Lucas Vitale | Orthofix Medical | 47 | |
Michael Pisetsky | Si Bone | 46 | |
Mehul Joshi | Pulmonx Corp | 63 | |
Mathieu Aussermeier | Integra LifeSciences Holdings | N/A | |
Badri Amurthur | LivaNova PLC | N/A | |
Sumi Shrishrimal | iRhythm Technologies | 45 | |
Gali Attias | Nano X Imaging | 45 | |
Joel Batts | Orthopediatrics Corp | N/A | |
Tamar Cohen | Nano X Imaging | 47 | |
Brent Lalomia | CONMED | 49 | |
Stephanie Walsh | Orthofix Medical | N/A |
Management Performance
Return On Equity | -0.0028 | ||||
Return On Asset | -0.0046 |
Axonics Modulation Leadership Team
Elected by the shareholders, the Axonics Modulation's board of directors comprises two types of representatives: Axonics Modulation inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics Modulation's management team and ensure that shareholders' interests are well served. Axonics Modulation's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics Modulation's outside directors are responsible for providing unbiased perspectives on the board's policies.
Alfred Ford, Chief Commercial Officer | ||
Danny Dearen, Chief Operating and Financial Officer | ||
MD MAS, Chief Officer | ||
Raymond Cohen, CEO, Director | ||
Rinda Sama, Chief Officer | ||
JD Esq, General VP | ||
Aaron Pettit, General Officer | ||
Kari Keese, Chief Officer | ||
John Woock, Chief Marketing Officer | ||
Neil Bhalodkar, Vice Relations | ||
Guangqiang Jiang, Chief Officer |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics Modulation a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.0028 | ||||
Return On Asset | -0.0046 | ||||
Profit Margin | (0) % | ||||
Operating Margin | 0.06 % | ||||
Current Valuation | 3.28 B | ||||
Shares Outstanding | 51.12 M | ||||
Shares Owned By Insiders | 1.27 % | ||||
Shares Owned By Institutions | 85.94 % | ||||
Number Of Shares Shorted | 3.6 M | ||||
Price To Earning | (10.68) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
V | Visa Class A | |
MSFT | Microsoft |
Additional Tools for Axonics Stock Analysis
When running Axonics Modulation's price analysis, check to measure Axonics Modulation's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axonics Modulation is operating at the current time. Most of Axonics Modulation's value examination focuses on studying past and present price action to predict the probability of Axonics Modulation's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Axonics Modulation's price. Additionally, you may evaluate how the addition of Axonics Modulation to your portfolios can decrease your overall portfolio volatility.